Beginning in mid-February 2008, the 1997-2007 online version of the Science Watch® newsletter, ESI-Topics.com, and in-cites.com, will all be featured together on the redesigned ScienceWatch.com. All previous content from the three sites will be permanently archived, and remain accessible from any existing bookmarks to the archived pages. No new content will be added to this site. Updates and new content (updated biweekly) are available at ScienceWatch.com now.

Fast Breaking Comments

By Alex Meissner

ESI Special Topics, October 2006
Citing URL - http://www.esi-topics.com/fbp/2006/october06-AlexMeissner.html

Alex Meissner answers a few questions about this month's fast breaking paper in the Multidisciplinary field.


From •>>October 2006

Field: Multidisciplinary
Article Title: Generation of nuclear transfer-derived pluripotent ES cells from cloned Cdx2-deficient blastocysts
Authors: Meissner, A;Jaenisch, R
Journal: NATURE
Volume: 439
Issue: 7073
Page: 212-215
Year: JAN 12 2006
* MIT, Whitehead Inst, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
* MIT, Whitehead Inst, Cambridge, MA 02142 USA.
* MIT, Dept Biol, Cambridge, MA 02142 USA.

ST:  Why do you think your paper is highly cited?


“Our paper described a modification of the current NT procedure, which would allow generating ES cells without destroying an embryo.”

The derivation of embryonic stem cells in the US and abroad is very controversial. One potential way to generate "customized" embryonic stem (ES) cells is through nuclear transfer (NT). Our paper described a modification of the current NT procedure, which would allow generating ES cells without destroying an embryo. This is achieved by blocking a gene that is essential for placental-development. The proof of the principle of this approach was demonstrated in a mouse model.

ST:  Does it describe a new discovery, methodology, or synthesis of knowledge?

It describes a number of previously described techniques that were combined to achieve the goal of reversibly blocking a gene that is required for the development of the extra-embryonic lineage, which will later form the placenta.

ST:  Could you summarize the significance of your paper in layman’s terms?

The paper is important, as it describes the first alternative approach ("altered nuclear transfer") that could be used to generate "customized" ES cells without destroying an embryo, as demonstrated in the mouse.

By blocking a gene that is required for the extra-embryonic cells prior to the nuclear transfer, only a disorganized clump of cells develops. This clump, however, still contains the cells that can be expanded into ES cells.

ST:  How did you become involved in this research, and were any problems encountered along the way?

The development of our procedure was only possible through combining a number of recently developed tools. Our lab is one of the few labs that had all the tools in place—nuclear transfer, RNA interference, etc.—and also has a major focus on stem cell biology.

ST:  Are there any social or political implications for your research?

The key issue is whether the "Altered Nuclear Transfer" (ANT) product is an embryo or a biological artifact, as William B. Hurlbut, a physician and consulting professor in the program of human biology at Stanford University, is arguing.

We have now gotten reactions by a number of ethicists, Catholic scholars, and even members of the Bush Administration, that they would not consider the ANT product as an embryo. This may open up funding from NIH for this type of research. Obviously, this is a highly charged political issue and we will have to see where this public discussion goes.End

Alex Meissner, Ph.D.
Whitehead Institute for Biomedical Research
MIT
Cambridge, MA, USA

ESI Special Topics, October 2006
Citing URL - http://www.esi-topics.com/fbp/2006/october06-AlexMeissner.html

•> Search Special Topics
Fast Breaking Papers Menu || All Topics Menu
Fast Breaking Papers Comments Menu
Help || About || Contact

ScienceWatch.com - Tracking Trends and Perfomance in Basic Research
Go to the new ScienceWatch.com

Write to the Webmaster with questions/comments. Terms of Usage.
The Research Services Group of Thomson Scientific |
(c) 2008 The Thomson Corporation.